Literature DB >> 16437231

[Surgical treatment of groin soft tissue defects].

H Fansa1, I C Warnecke, S Brüner, O Frerichs.   

Abstract

BACKGROUND: Treatment of groin defects remains challenging due to their location and origin. Such defects commonly result from resection of tumours but can also occur after surgical or medical therapy.
MATERIAL AND METHODS: From 2003 to 2005, 11 patients were treated with groin defects following radiation therapy and resection of lymph node metastasis, primary carcinoma, and sarcoma. Seven patients received wound closure with rectus femoris muscle flaps, and three had vertical rectus abdominis muscle flaps. One patient was amputated at the hip, and the defect was covered with dorsally pedicled muscle and skin flaps.
RESULTS: All flaps healed primarily. There were no secondary infections or lymphorrhea.
CONCLUSION: The flaps described here are well vascularised standard flaps which are easily harvested with no major donor site morbidity. They provide sufficient coverage for the groin, reduce long-term conservative treatment, hospitalisation, and problems such as scar contracture.

Entities:  

Mesh:

Year:  2006        PMID: 16437231     DOI: 10.1007/s00104-005-1131-x

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  16 in total

1.  Primary reconstruction to avoid wound breakdown following groin block dissection.

Authors:  V Abraham; R Ravi; B R Shrivastava
Journal:  Br J Plast Surg       Date:  1992-04

2.  Surgical management of groin lymphatic complications after arterial bypass surgery.

Authors:  Michele A Shermak; Kristen Yee; Lesley Wong; Calvin E Jones; James Wong
Journal:  Plast Reconstr Surg       Date:  2005-06       Impact factor: 4.730

3.  Morbidity following groin dissection for penile carcinoma.

Authors:  R Ravi
Journal:  Br J Urol       Date:  1993-12

4.  Donor-site morbidity of the pedicled rectus femoris muscle flap.

Authors:  Adrien Daigeler; Tomislav Dodic; Friedemann Awiszus; Wolfgang Schneider; Hisham Fansa
Journal:  Plast Reconstr Surg       Date:  2005-03       Impact factor: 4.730

5.  Management of complex groin wounds: preferred use of the rectus femoris muscle flap.

Authors:  Joseph D Alkon; Andrew Smith; Joseph E Losee; Karl A Illig; Richard M Green; Joseph M Serletti
Journal:  Plast Reconstr Surg       Date:  2005-03       Impact factor: 4.730

6.  The concept of fillet flaps: classification, indications, and analysis of their clinical value.

Authors:  M V Küntscher; D Erdmann; H H Homann; H U Steinau; S L Levin; G Germann
Journal:  Plast Reconstr Surg       Date:  2001-09-15       Impact factor: 4.730

7.  Management of early groin vascular bypass graft infections with sartorius and rectus femoris flaps.

Authors:  Amy S Colwell; Magruder C Donaldson; Michael Belkin; Dennis P Orgill
Journal:  Ann Plast Surg       Date:  2004-01       Impact factor: 1.539

8.  The dissection of the rectus abdominis myocutaneous flap with complete preservation of the anterior rectus sheath.

Authors:  D Erni; Y D Harder
Journal:  Br J Plast Surg       Date:  2003-06

9.  [Abdominal wall reconstruction with pedicled rectus femoris muscle flap].

Authors:  A Daigeler; H Fansa; S Altmann; F Awiszus; W Schneider
Journal:  Chirurg       Date:  2004-06       Impact factor: 0.955

10.  [Therapy of advanced penis carcinoma].

Authors:  T Otto; J Suhr; S Krege; H Rübben
Journal:  Urologe A       Date:  2003-11       Impact factor: 0.639

View more
  2 in total

Review 1.  [Locoregional solutions for groin defects : Coverage after vascular surgery].

Authors:  M Cerny; Y Harder; A Zimmermann; H-H Eckstein; H-G Machens; J-T Schantz; T L Schenck
Journal:  Chirurg       Date:  2017-01       Impact factor: 0.955

2.  The versatility of the pedicled vertical rectus abdominis myocutaneous flap in oncologic patients.

Authors:  Adrien Daigeler; Maria Simidjiiska-Belyaeva; Daniel Drücke; Ole Goertz; Tobias Hirsch; Christian Soimaru; Marcus Lehnhardt; Hans-Ulrich Steinau
Journal:  Langenbecks Arch Surg       Date:  2011-07-16       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.